ClinicalTrials.gg
CompletedNCT02526524Updated Apr 27, 2018Results posted

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

A Phase 2 interventional study of Met DR and Met IR in Type 2 Diabetes Mellitus, sponsored by Elcelyx Therapeutics, Inc.. Completed at 137 sites in 2 countries. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2018-04-27.

Sponsored by Elcelyx Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
571
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
36th of 287
571 · median 100
Started
2015
with 11 others
Phase 2
23 of 293
3 open now
Registered
204th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 36th largest by enrollment of the 287 interventional ones that give a count, is one of 12 that started in 2015, is one of 23 in phase 2, and was the 204th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to compare the glycemic effects of delayed-release metformin (Met DR) to placebo in subjects with type 2 diabetes mellitus (T2DM) over 16 weeks. The study is designed to evaluate several doses of Met DR (600 to 1500 mg once daily in the morning [qAM]) compared to placebo. A single-blind reference treatment of 2000 mg metformin immediate-release (Met IR) per day administered as equal divided doses (1000 mg Met IR BID) will also be included.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is at least 25 years old at Visit 1 (Screening).
  2. Is male, or is female and meets all of the following criteria:

    1. Not breastfeeding
    2. Negative pregnancy test result at Visit 1 (not applicable to or surgically sterile females)
    3. Surgically sterile, postmenopausal, or if of , must practice and be willing to continue to practice appropriate during the entire duration of the study.
  3. (BMI) 20.0 to 45.0 kg/m² (inclusive) at Visit 1 (Screening).
  4. Has a physical examination with no abnormalities as judged by the investigator.
  5. Has T2DM and an of 7.5% to 10.5%, inclusive, at Visit 1.
  6. Has an estimated (eGFR) value of ≥60 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation.
  7. Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Visit 1:

    1. Thiazolidinedione, sulfonylurea, dipeptidyl peptidase-4 inhibitors, and alpha-glucosidase inhibitors
    2. Hormone replacement therapy (female subjects) and testosterone (male subjects)
    3. Oral contraceptives (female subjects)
    4. Antihypertensive agents
    5. Lipid-lowering agents
    6. Thyroid replacement therapy
    7. Antidepressant agents
  8. Ability to understand and willingness to adhere to protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Has a medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions:

    1. Hepatic disease
    2. Gastrointestinal disease
    3. Endocrine disorder (T2DM is allowed)
    4. Cardiovascular disease
    5. Central nervous system diseases
    6. Psychiatric or neurological disorders
    7. Organ transplantation
    8. Chronic or acute infection
    9. Orthostatic hypotension, fainting spells or blackouts
    10. Allergy or .
  2. A history of diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycemia within the past year.
  3. Prior major surgery of any kind within 6 months of Visit 1.
  4. A history of >3% weight change within 3 months of Visit 1.
  5. A clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormality, other than that related to T2DM, judged by the investigator to be clinically significant at Visit 1.
  6. An or aspartate aminotransferase result >2.5 × (ULN) or a result >1.5 × ULN.
  7. A physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.
  8. Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following excluded medications:

    1. Metformin within 2 months of Visit 1 (Screening)
    2. Insulin within 2 weeks of Visit 1 (Screening) or for more than 1 week within 3 months of Visit 1 (Screening)
    3. Glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter 2 inhibitors within 3 months of Visit 1
    4. Drugs known to affect body weight, including prescription medications and over-the-counter anti obesity agents within 3 months of Visit 1.
    5. Systemic by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of Visit 1
    6. Planned use of any drug treatment that affects gastric pH (prescription or over-the-counter), such as H2-receptor antagonists and proton pump inhibitors, after Visit 2 (Week -2), or planned chronic use of any antacids (i.e., more than twice per week) after Visit 2 (Week -2)
    7. Cationic drugs that are eliminated by renal tubular secretion within 1 week of Visit 1.
    8. Iodinated contrast dye within 1 week prior to Visit 1.
    9. drug within 2 months (or five half-lives of the investigational drug, whichever is greater) of the date of the first dose of randomized study medication.
    10. Met DR or double-blind matching placebo for Met DR at any time prior to Visit 1 (Screening)
  9. Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.
  10. Had a blood transfusion or experienced significant blood loss (i.e., >500 mL), including loss due to blood donation, within 2 months prior to Visit 1 (Screening), or is planning to donate blood during the study.
  11. Has known immune system based allergies or hypersensitivity to any component of study treatment. A history of gastrointestinal intolerance to metformin is not exclusionary.
  12. Is employed by Elcelyx Therapeutics, Inc. (that is an employee, contract worker, or designee of the company).
  13. Has a fasting plasma glucose value >270 mg/dL at Visit 1 (Screening), Visit 2 (Week -2), and an unscheduled visit to be completed within 1 week following Visit 2. The unscheduled visit is to be completed only for subjects with a fasting plasma glucose value >270 mg/dL at Visit 1 and Visit 2.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
571 participants (actual)

Study arms

  • Experimental
    600 mg Met DR qAM

    600 mg metformin delayed-release once daily in the morning

    Drug: Met DR

  • Experimental
    900 mg Met DR qAM

    900 mg metformin delayed-release once daily in the morning

    Drug: Met DR

  • Experimental
    1200 mg Met DR qAM

    1200 mg metformin delayed-release once daily in the morning

    Drug: Met DR

  • Experimental
    1500 mg Met DR qAM

    1500 mg metformin delayed-release once daily in the morning

    Drug: Met DR

  • Placebo comparator
    Placebo-1

    placebo match for 600 and 1200 mg Met DR qAM treatment groups

    Drug: Placebo

  • Placebo comparator
    Placebo-2

    placebo match for 900 and 1500 mg Met DR qAM treatment groups

    Drug: Placebo

  • Active comparator
    2000 mg Met IR

    1000 mg metformin immediate-release twice daily

    Drug: Met IR

Interventions

  • DrugMet DR

    metformin delayed-release tablets

  • DrugMet IR

    metformin immediate-release tablets

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Change in HbA1c (%) at 16 Weeks

    Time frame: Baseline and 16 weeks after the first dose of study medication

07

Results

Posted Apr 27, 2018

Participant flow

Participant flow — Overall Study
Milestone600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IR
Started949596969694
Completed828670897273
Not completed1292672421
Withdrew: Withdrawal by subject336195
Withdrew: Adverse event324268
Withdrew: Lost to follow-up238125
Withdrew: Protocol violation315343
Withdrew: Loss of glucose control003020
Withdrew: Physician decision000010
Withdrew: Sponsor decision100000

Outcome measures

PrimaryChange in HbA1c (%) at 16 Weeks
Time frame:
Baseline and 16 weeks after the first dose of study medication
Reported as:
Least squares mean · % glycated haemoglobin
Change in HbA1c (%) at 16 Weeks
% glycated haemoglobin600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IR
Change in HbA1c (%) at 16 Weeks-0.33 ± 0.129-0.40 ± 0.123-0.49 ± 0.129-0.62 ± 0.124-0.06 ± 0.131-1.10 ± 0.129
Statistical analysis
  • 600 mg Met DR qAM vs Placebo · Mixed Models Analysis · p = 0.1449 · Ls mean: -0.27 · 95% CI -0.63 to 0.09Included treatment, visit, and treatment-by-visit interaction as fixed effects, and HbA1c value at Baseline as a covariate.
  • 900 mg Met DR qAM vs Placebo · Mixed Models Analysis · p = 0.0643 · Ls mean: -0.33 · 95% CI -0.69 to 0.02Included treatment, visit, and treatment-by-visit interaction as fixed effects, and HbA1c value at Baseline as a covariate.
  • 1200 mg Met DR qAM vs Placebo · Mixed Models Analysis · p = 0.0214 · Ls means: -0.42 · 95% CI -0.79 to -0.06Included treatment, visit, and treatment-by-visit interaction as fixed effects, and HbA1c value at Baseline as a covariate.
  • 1500 mg Met DR qAM vs Placebo · Mixed Models Analysis · p = 0.0022 · Ls mean: -0.55 · 95% CI -0.91 to -0.20Included treatment, visit, and treatment-by-visit interaction as fixed effects, and HbA1c value at Baseline as a covariate.
  • Placebo vs 2000 mg Met IR · Mixed Models Analysis · p = <0.0001 · Ls mean: -1.03 · 95% CI -1.39 to -0.67Included treatment, visit, and treatment-by-visit interaction as fixed effects, and HbA1c value at Baseline as a covariate.

Adverse events

Collected over 16 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
600 mg Met DR qAM0/94 (0%)1/94 (1.1%)19/94 (20.2%)
900 mg Met DR qAM0/95 (0%)0/95 (0%)24/95 (25.3%)
1200 mg Met DR qAM0/96 (0%)4/96 (4.2%)19/96 (19.8%)
1500 mg Met DR qAM0/96 (0%)1/96 (1%)20/96 (20.8%)
Placebo1/96 (1%)4/96 (4.2%)17/96 (17.7%)
2000 mg Met IR0/94 (0%)1/94 (1.1%)23/94 (24.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
Event600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IR
Gastrooesophageal reflux diseaseGastrointestinal disorders0/940/950/960/960/961/94
HidradenitisSkin and subcutaneous tissue disorders1/940/950/960/960/960/94
Colitis ischaemicGastrointestinal disorders0/940/950/960/961/960/94
DeathGeneral disorders0/940/950/960/961/960/94
Arthritis bacterialInfections and infestations0/940/951/960/960/960/94
OsteomyelitisInfections and infestations0/940/950/960/961/960/94
Pelvic inflammatory diseaseInfections and infestations0/940/950/960/961/960/94
ObesityMetabolism and nutrition disorders0/940/951/960/960/960/94
ArthritisMusculoskeletal and connective tissue disorders0/940/950/961/960/960/94
Pain in extremityMusculoskeletal and connective tissue disorders0/940/951/960/960/960/94
Most frequent other events
Most frequent other events
Event600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IR
DiarrhoeaGastrointestinal disorders7/947/9511/9611/960/9613/94
HyperglycemiaMetabolism and nutrition disorders8/9410/957/968/9610/965/94
NauseaGastrointestinal disorders3/943/951/963/961/969/94
Upper respiratory tract infectionInfections and infestations1/945/951/960/962/962/94
Worsening Type 2 diabetes mellitusMetabolism and nutrition disorders3/941/950/960/965/960/94

Baseline characteristics

Intent-to-Treat Population: Subjects who took at least one dose of randomized study medication.

Age, Continuous
Age, Continuous(years)600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IRTotal
Mean56 ± 10.255 ± 10.555 ± 11.155 ± 8.957 ± 11.057 ± 11.156 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IRTotal
Female463845425345269
Male485751544349302
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IRTotal
Hispanic or Latino364441423745245
Not Hispanic or Latino585155545949326
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IRTotal
American Indian or Alaska Native1000012
Asian36335222
Native Hawaiian or Other Pacific Islander0001102
Black or African American147231917888
White758270737282454
More than one race1000012
Unknown or Not Reported0000101
Body Weight
Body Weight(kg)600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IRTotal
Mean94 ± 19.989 ± 18.593 ± 20.995 ± 22.286 ± 17.189 ± 21.391 ± 20.2
Body Mass Index
Body Mass Index(kg/m²)600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IRTotal
Mean33 ± 5.132 ± 5.532 ± 5.933 ± 5.831 ± 5.132 ± 5.432 ± 5.5
HbA1c
HbA1c(%)600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IRTotal
Mean8.6 ± 0.858.7 ± 0.828.7 ± 0.908.6 ± 0.948.6 ± 0.878.6 ± 0.928.6 ± 0.88
HbA1c stratum
HbA1c stratum(Participants)600 mg Met DR qAM900 mg Met DR qAM1200 mg Met DR qAM1500 mg Met DR qAMPlacebo2000 mg Met IRTotal
<8.5%454546464545272
≥8.5%495050505149299

5 further baseline measures are reported on the registry.

08

Study locations

137 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • Central Alabama Research
    Birmingham, Alabama 35209, United States
  • Achieve Clinical Research, LLC
    Birmingham, Alabama 35216, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Terence T. Hart, MD
    Tuscumbia, Alabama 35674, United States
  • Radiant Research - Phoenix
    Chandler, Arizona 85224, United States
  • Arrowhead Health Centers
    Glendale, Arizona 85306, United States
  • Holland Center for Family Health, LTD
    Peoria, Arizona 85381, United States
  • Elite Clinical Studies
    Phoenix, Arizona 85018, United States
  • Thunderbird Internal Medicine - Indian School Rd.
    Phoenix, Arizona 85037, United States
  • Clinical Research Institute of Arizona, LLC
    Surprise, Arizona 85374, United States
  • Summit Clinical Trials Center
    Fayetteville, Arkansas 72703, United States
  • Searcy Medical Center
    Searcy, Arkansas 72143, United States
  • Advanced Metabolic Care & Research Institute (AMCR)
    Escondido, California 92025, United States
  • MD Studies, Inc.
    Fountain Valley, California 92708, United States
  • National Research Institute
    Huntington Park, California 90255, United States
  • Scripps Whittier Diabetes Institute
    La Jolla, California 92037, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Catalina Research Institute
    Montclair, California 91763, United States
  • SRSD, Inc. dba Synergy San Diego
    National City, California 91950, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • Pacific Research Partners, LLC
    Oakland, California 94607, United States
  • SDS Clinical Trials, Inc.
    Orange, California 92868, United States
  • Center for Clinical Trials of Sacramento
    Sacramento, California 95823, United States
  • Center for Clinical Trials of Scaramento
    Sacramento, California 95823, United States
  • Superior Research LLC
    Sacramento, California 95825, United States
  • Syrentis Clinical Research (formerly Research Across America)
    Santa Ana, California 92705, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Clinical Trial Investigators
    Tustin, California 92780, United States
  • Infosphere Clinical Research
    Van Nuys, California 91405, United States
  • Colorado Springs Health Partners
    Colorado Springs, Colorado 80906, United States
  • Creekside Endocrine Associates
    Denver, Colorado 80209, United States
  • Meridien Research - Brooksville
    Brooksville, Florida 34601, United States
  • ALL Medical Research, LLC
    Cooper City, Florida 33024, United States
  • Neostart Corporation dba AGA Clinical Trials
    Hialeah, Florida 33012, United States
  • Care Partners Clinical Research
    Jacksonville, Florida 32277, United States
  • Health Awareness, Inc.
    Jupiter, Florida 33458, United States
  • Family Health Care Clinical Studies
    Kissimmee, Florida 34741, United States
  • Clinical Research of Central Florida-Lakeland
    Lakeland, Florida 33810, United States
  • Clinical Pharmacology of Miami, Inc.
    Miami, Florida 33014, United States
  • Tellus Clinical Research, Inc.
    Miami, Florida 33173, United States
  • Internal Research Associates LLC - Breton
    Miami, Florida 33183, United States
  • Clinical Neuroscience Solutions, Inc. Healthcare Orlando
    Orlando, Florida 32801, United States
  • Ormond Medical Arts Pharmaceutical Research Center
    Ormond Beach, Florida 32174, United States
  • Private Practice - Andres Patron, DO
    Pembroke Pines, Florida 33026, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Meridien Reserach - St. Petersburg
    Saint Petersburg, Florida 33709, United States
  • Clinical Reserch Trials of Florida
    Tampa, Florida 33607, United States
  • Meridien Research - Tampa
    Tampa, Florida 33634, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • Biofortis, Inc.
    Addison, Illinois 60101, United States
  • AMR Sakeena Research
    Aurora, Illinois 60506, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Evanston Premier Healthcare Research LLC
    Evanston, Illinois 60201, United States
  • Buynak Clinical Research, PC
    Valparaiso, Indiana 46383, United States
  • The Iowa Clinic; Cardiovascular Services
    West Des Moines, Iowa 50266, United States
  • Heartland Research Associates, LLC - Augusta
    Augusta, Kansas 67010, United States
  • Cotton-O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Otrimed
    Edgewood, Kentucky 41017, United States
  • Kentucky Diabetes Endocrinology Center
    Lexington, Kentucky 40503, United States
  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
    Louisville, Kentucky 40213, United States
  • Four Rivers Clinical Research
    Paducah, Kentucky 42003, United States
  • Avant Research Associates
    Crowley, Louisiana 70526, United States
  • Centex Studies, Inc. - lake Charles
    Lake Charles, Louisiana 70601, United States
  • Columbia Medical Practice
    Columbia, Maryland 21045, United States
  • Medstar Health Research Institute
    Hyattsville, Maryland 20782, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Beacon Clinical Research
    Quincy, Massachusetts 02169, United States
  • Radiant Research - Edina
    Edina, Minnesota 55435, United States
  • Planters Clinic
    Port Gibson, Mississippi 39150, United States
  • Mercury Street Medical Group, PLLC
    Butte, Montana 59701, United States
  • Quality Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • Heartland Clinical Research
    Omaha, Nebraska 68134, United States
  • Alliance Against Diabetes
    Las Vegas, Nevada 89101, United States
  • AB Clinical Trials
    Las Vegas, Nevada 89119, United States
  • Palm Medical Research
    Las Vegas, Nevada 89128, United States
  • Ingham Neuroscience Group, LLC
    Las Vegas, Nevada 89146, United States
  • Comprehensive Clinical Research
    Berlin, New Jersey 08009, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • Albuquerque Neuroscience, Inc.
    Albuquerque, New Mexico 87109, United States
  • NY Scientific
    Brooklyn, New York 11235, United States
  • Long Island Gastrointestinal Research Group
    Great Neck, New York 11023, United States
  • Mid-Hudson Medical Research, PLLC
    Hopewell Junction, New York 12533, United States
  • Great Lakes Medical Research
    Westfield, New York 14787, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • Triad Clinical Trials LLC
    Greensboro, North Carolina 27410, United States
  • PMG Research of Rocky Mount
    Rocky Mount, North Carolina 27804, United States
  • PMG Research of Salisbury, LLC
    Salisbury, North Carolina 28144, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Sterling Research Group, Ltd
    Cincinnati, Ohio 45219, United States
  • Metabolic Atherosclerosis Research Center
    Cincinnati, Ohio 45227, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45242, United States
  • Urgent Care Specialists, LLC DBA Hometown Urgent Care and Occupational Health
    Columbus, Ohio 43214, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Hometown Urgent Care and Research - Huber Heights
    Huber Heights, Ohio 45424, United States
  • RAS Health LTD
    Marion, Ohio 43302, United States
  • Summit Reserach Group, LLC
    Stow, Ohio 44224, United States
  • COR Clinical Research, LLC
    Oklahoma City, Oklahoma 73103, United States

Showing the first 100 of 137 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Henry RR, Frias JP, Walsh B, Skare S, Hemming J, Burns C, Bicsak TA, Baron A, Fineman M. Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PLoS One. 2018 Sep 25;13(9):e0203946. doi: 10.1371/journal.pone.0203946. eCollection 2018. PubMed 30252913 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2015
First posted
Aug 18, 2015
Start
Sep 2015
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results first posted
Apr 27, 2018
Last update
Apr 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02526524
Lead sponsor
Elcelyx Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 18, 2015
Start date
Sep 2015
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
Apr 27, 2018
Last update
Apr 27, 2018

Study contacts

Juan P Frias, MD
principal investigator · National Research Institute - Wilshire

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion